Oxygesic Dispersa (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxygesic Dispersa, is an opioid analgesic presented as a strength/form for oral use. It is prescribed for management of moderate to severe pain in adult patients. GNH USA supplies Oxygesic Dispersa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxygesic Dispersa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxygesic Dispersa is an opioid analgesic that acts on the central nervous system to relieve pain.

- Acute postoperative pain: provides effective relief following surgical procedures. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: reduces intensity of long‑standing pain unresponsive to non‑opioid therapies. - Traumatic injury pain: alleviates pain from major injuries such as fractures or burns. - Palliative care pain: improves comfort in end‑of‑life care settings.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness. - Dry mouth: reduced salivation. - Pruritus: mild itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or addiction: potential for misuse. - Seizures: rare convulsive episodes. - Anaphylaxis: acute allergic reaction with hives or swelling. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Oxygesic Dispersa, clinicians should consider several safety measures.

- Assess pain severity: confirm that opioid therapy is appropriate. - Evaluate respiratory function: monitor for signs of depression. - Review patient history: check for substance use disorder risk. - Adjust for renal/hepatic impairment: dose may need modification. - Avoid concurrent CNS depressants: limit additive sedation. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxygesic Dispersa can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - Central nervous system depressants: may intensify sedation and respiratory effects. - MAO‑inhibitors: can precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen constipation. - CYP3A4 inhibitors (e.g., ketoconazole): increase oxycodat e levels. - CYP3A4 inducers (e.g., rifampicin): reduce oxycodone concentrations. - Diuretics: may enhance hypotensive effects. - Antidepressants (SSRIs): potential for serotonin syndrome in rare cases.